The U.S. Food and Drug Administration has granted approval for the Abbreviated New Drug Application (ANDA) 077491 submitted by Amici Pharma, Inc. for generic Pravastatin Sodium tablets.
The approved product is an oral tablet available in six strengths – 10 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg – each marketed as a prescription medication.
FDA submission records show approval of labeling (submission numbers 9 and 5) with status dates June 6 2026 and September 9 2019, and approval of a manufacturing (CMC) submission (number 7) dated August 6 2026.
The product is listed under the human prescription drug category with NDC codes ranging from 69292‑101‑10 to 69292‑104‑90.
Actualizaciones regulatorias10 sept 2026•1 min de lectura
FDA Approves Amici Pharma’s Generic Pravastatin Sodium Tablets (ANDA 077491)
The FDA has approved the ANDA 077491 for Pravastatin Sodium tablets from Amici Pharma, covering strengths from 10 mg to 80 mg.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración